Atossa Therapeutics, Inc.
$0.8305
Stock Quotes & Analysis
ATOS3.74%
$0.8305
Latest AAPL News (Need to figure out how to make this dynamic)
test
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Atossa Therapeutics, Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: ATOS
Exchange: NCM
Employees: 12
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
 | 107 Spring Street, Seattle, WA, United States |
 | 206 588 0256 |
 | https://www.atossatherapeutics.com |